神經調控設備市場規模、佔有率和趨勢分析 |全球| 2026–2032 | 包括脊髓刺激、深部腦部刺激及其他3個類別

2025年全球神經調控設備市場價值59億美元。預計該市場將以4.4%的複合年成長率成長，到2032年達到80億美元。

本報告涵蓋脊髓刺激 (SCS)、深部腦部刺激 (DBS)、薦椎神經刺激、迷走神經刺激和胃電刺激。 SCS 部分按設備類型（特別是發生器和導線）進行進一步分析。本報告定量分析了手術數量、銷量、平均售價 (ASP)、市場規模、成長率和企業市場占有率，包括截至 2022 年的歷史數據和截至 2032 年的預測數據。

預計在整個預測期內，該市場將保持穩定成長，這主要得益於手術數量的增加以及五大類設備臨床應用範圍的擴大。儘管銷售量預計將穩定成長，但隨著市場日趨成熟，成長率將逐漸放緩。脊髓刺激（SCS）技術的進步，包括電池壽命延長、設備小型化、可充電植入系統以及高頻刺激和脈衝串刺激等新型刺激模式，都支撐著強勁的潛在需求。

在預測期內，平均售價（ASP）預計將略有下降，反映出市場價格壓力和競爭趨勢。整體市場價值成長將保持正成長，主要受銷售成長的推動。患者對可充電設備的充電依從性以及專利限制導致部分競爭對手無法獲得高頻刺激技術，是限制市場動態的關鍵結構性阻礙因素。

市場概覽

全球神經調控設備市場涵蓋多種植入式電刺激療法，這些療法透過調節神經活動來治療各種慢性疾病。脊髓刺激是規模最大、商業性最活躍的細分市場，主要用於治療慢性疼痛。深部腦部刺激用於治療帕金森氏症和原發性顫抖等運動障礙。薦椎神經刺激用於治療膀胱和腸道功能障礙，迷走神經刺激用於治療癲癇和難治性憂鬱症，胃電刺激用於治療胃麻痺。這五種療法服務於全球主要市場中日益成長的慢性疾病患者群體。

預測期內市場成長將主要由銷售成長驅動。這是因為，儘管各療程領域的銷售量將會增加，但由於價格競爭和市場成熟，平均售價（ASP）將逐漸下降。隨著市場在成熟區域逐步成熟，銷售成長速度預計將逐漸放緩。儘管成長放緩，但由於適應症的擴大、醫生採納率的提高以及產品創新，市場依然展現出強勁的潛在需求，這些因素拓寬了患者的適用範圍，並增強了他們對治療的信心。

在神經調控領域，脊髓刺激（SCS）是產品創新最活躍的領域。可充電發生器技術的進步、設備的微型化和輕量化、編程選項的擴展以及包括高頻刺激和脈衝串刺激在內的新型刺激模式的出現，都提高了SCS的臨床應用價值，並擴大了其適用患者群體。無線和微創注射設備也正在進入市場，這些設備有望作為下一代給藥方式，進一步擴大SCS的應用範圍，尤其適用於那些傳統植入手術存在重大障礙的患者和醫療機構。

市場競爭格局集中度適中，美敦力、雅培和波士頓科學佔據主導地位，而像Nebro這樣的專業公司則憑藉取得專利的高頻刺激技術建立了差異化優勢。來自競爭的價格壓力以及可充電系統（更換頻率更低）的普及，抑制了各細分市場發生器和導線平均售價（ASP）的上漲趨勢，同時提升了患者的價值提案，因為這些設備可以減少再次手術的次數，並延長治療週期。

市場促進因素

技術進步

脊髓刺激（SCS）領域的持續創新支撐著強勁的市場需求，並擴大了適用患者群體。植入式可充電系統的電池壽命延長顯著提升了其對患者的提案，某些產品的電池壽命已獲批准長達11年，從而減少了手術更換的頻率。雖然電池壽命延長減少了每位患者所需的更換設備數量，但它擴大了目標患者群體，使SCS成為那些不願完全依賴藥物治療的患者更具吸引力的長期治療選擇。包括更小更輕的設備以及更豐富的無線編程選項在內的廣泛進步，也在改善患者體驗並提升醫生的治療柔軟性。高頻刺激、脈衝串刺激和無線注射設備等形式代表了SCS創新的前沿，每種形式都具有獨特的臨床特徵，並拓寬了醫生進行植入手術時可用的治療工具範圍。

擴大充電植入的應用

目前，所有主要的脊髓刺激器（SCS）製造商都提供可充電式產生器系統，與一次電池（不可充電）的替代方案相比，這些產品越來越受歡迎。由於可充電式產生器可以進行外部電池充電，因此在整個治療期間所需的再次手術次數更少，與壽命較短的一次電池產生器相比，顯著延長了植入設備的有效使用壽命。再次手術次數的減少降低了長期醫療成本，並提高了SCS療法的整體經濟效益。這進一步促進了醫生、保險公司和患者對SCS療法的接受度，因為他們評估整個治療期間的醫療保健成本。此外，與不可充電式產生器相比，可充電式發生器在植入時的成本顯著降低，這也進一步促進了其在各種醫療機構和保險公司的應用。

市場限制

患者依從性

雖然從成本和再次手術率的角度來看，過渡到可充電脊髓刺激器 (SCS) 設備是有益的，但它也引入了「患者依從性」的要求，而這是使用一次電池供電的發生器所沒有的。使用可充電系統時，患者必須定期使用外部充電器為植入的裝置充電。如果未能堅持充電，隨著電池電量的下降，治療效果也會降低。無法遵守充電計劃的患者可能會出現症狀復發和治療滿意度下降，這可能導致治療中斷。這種依從性負擔可能使充電設備不適用於某些患者群體，例如老年人或手部靈活性有限的患者，這也限制了可充電系統在所有患者群體中完全取代不可充電設備的能力。

因專利侵權而受到的限制

自2010年以來，Nevro已將其取得專利的HF10射頻療法應用於其脊髓刺激（SCS）系統，該技術已獲得FDA認證，顯示其優於傳統的SCS療法。 2019年初，Nevro對Stimwave提起專利侵權訴訟，後者當時正在開發一種能夠以10 kHz頻率運作的微創SCS設備。該訴訟導致法院對Stimwave發布了部分禁令，限制Stimwave和其他SCS競爭對手的刺激頻率不得超過3 kHz。這實際上使Nevro成為唯一一家能夠以10 kHz頻率提供無感覺異常射頻SCS療法的公司，從而在該臨床差異化治療領域建立了顯著的競爭優勢，並限制了其他製造商在射頻刺激領域直接競爭的能力。

目錄

調查方法

• 第一步：專案推出與團隊組建
• 步驟二：資料系統開發與二次調查實施
• 步驟三：準備面試設計問卷
• 第四步：進行初步調查
• 第五步：調查分析：基準估計
• 第六步：市場預測與分析
• 第七步：辨識策略機遇
• 步驟 8：最終確認和市場發布
• 步驟九：客戶回饋與市場監測

全球關稅的影響

神經調控設備市場

• 執行摘要
  • 全球神經調控設備市場概覽
  • 競爭分析
  • 涵蓋的治療
  • 目標市場
  • 目標區域
• 介紹
  • 脊髓刺激療法
  • 深部腦部刺激療法
  • 薦椎神經刺激療法
  • 迷走神經刺激療法
  • 胃電刺激
• 治療次數
  • 神經調控手術總數
  • 脊髓刺激手術次數
  • 進行的深部腦部刺激手術數量
  • 薦椎神經刺激手術次數
  • 迷走神經刺激手術次數
  • 胃電刺激療法
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 神經調控設備市場（整體市場）
  • 脊髓刺激市場
  • 深部腦部刺激市場
  • 薦椎神經刺激市場
  • 迷走神經刺激市場
  • 胃電刺激市場
• 促進因素和抑制因素
  • 市場促進因素
  • 市場限制因素
• 競爭性市佔率分析

附錄

The global neuromodulation device market was valued at $5.9 billion in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 4.4%, reaching $8 billion by 2032.

This report covers spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation, vagus nerve stimulation, and gastric electric stimulation. The SCS segment is further analyzed by device type into generators and leads. The report quantifies procedure numbers, unit sales, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.

The market is expected to demonstrate steady growth over the forecast period, driven by increasing procedure volumes and expanding clinical applications across the five device categories. Unit sales are projected to grow at a solid pace, though growth rates moderate gradually as the market matures. Technological advancements in SCS, including extended battery life, device miniaturization, rechargeable implant systems, and new stimulation modalities such as high-frequency and burst stimulation, are sustaining strong underlying demand.

ASPs are expected to decrease slightly over the forecast period, reflecting pricing pressures and competitive dynamics within the market. Overall market value growth remains positive and is primarily volume-driven. Patient compliance with rechargeable device charging and patent constraints limiting access to high-frequency stimulation technology for certain competitors represent the primary structural limiters on market dynamics.

Market Overview

The global neuromodulation device market encompasses a diverse set of implantable electrical stimulation therapies that modulate neural activity to treat a range of chronic conditions. Spinal cord stimulation is the largest and most commercially active segment, used primarily for the management of chronic pain. Deep brain stimulation addresses movement disorders such as Parkinson's disease and essential tremor. Sacral nerve stimulation targets bladder and bowel dysfunction, vagus nerve stimulation is used in epilepsy and treatment-resistant depression, and gastric electric stimulation provides therapy for gastroparesis. Together, these five modalities address a broad and growing chronic condition patient population across major global markets.

Market growth across the forecast period is primarily volume-driven, as unit sales increase across therapy areas while ASPs trend modestly downward due to pricing competition and market maturation. The pace of unit volume growth is expected to moderate gradually as the market moves through successive stages of maturity in established geographies. Despite this moderation, the market continues to show strong underlying demand as indications expand, physician adoption grows, and product innovations increase both patient eligibility and procedural confidence.

The SCS segment is experiencing the most active product innovation within the neuromodulation space. Advances in rechargeable generator technology, reductions in device size and weight, expanded programming options, and new stimulation modes including high-frequency and burst stimulation have broadened the clinical appeal of SCS and expanded the patient profiles for which it is considered appropriate. Wireless and minimally invasive injectable device formats are also entering the market, representing a next-generation delivery approach that could further expand adoption, particularly among patients or settings where traditional implantation procedures present a higher barrier.

The competitive landscape is moderately concentrated, with Medtronic, Abbott, and Boston Scientific holding leading positions alongside specialty companies including Nevro, which holds a differentiated position through its patented high-frequency stimulation technology. Pricing pressure from competitive dynamics and the transition to rechargeable systems, which carry lower replacement frequency, are both moderating ASP trajectories across the generator and leads segments while increasing the value proposition for patients who remain on therapy longer with fewer revision surgeries.

Market Drivers

Technological Advancements

Continuous innovation across the SCS segment is sustaining strong demand and expanding the range of patients who are suitable candidates for therapy. Extended battery life in implantable rechargeable systems has significantly improved the value proposition for patients, with approvals for battery life of up to 11 years in certain products reducing the frequency of surgical replacements. While longer battery life reduces the number of replacement unit sales per patient, it expands the addressable population by making SCS a more attractive long-term option for patients who prefer not to rely on medication alone. Broader advancements in device miniaturization, decreasing device weight, and expanded wireless programming options are also improving patient experience and physician flexibility. Higher-frequency stimulation, burst stimulation, and wireless injectable device formats represent the leading edge of SCS innovation, with each modality offering distinct clinical profiles and expanding the therapeutic toolset available to implanting physicians.

Increased Use of Rechargeable Implants

All major SCS manufacturers now offer rechargeable generator systems, and these products continue to grow in preference over primary cell (non-rechargeable) alternatives. Rechargeable generators require fewer revision surgeries over the life of the therapy because their batteries can be replenished externally, extending the useful implant life significantly compared to shorter-lived primary cell generators. This reduction in surgical revisions lowers long-term healthcare costs and improves the overall economics of SCS therapy, supporting broader adoption among physicians, payers, and patients who evaluate the cost of care over the full treatment period. Rechargeable generators are also notably less expensive than non-rechargeable alternatives at the point of implant, further supporting their adoption across a range of care settings and payer environments.

Market Limiters

Patient Compliance

The shift toward rechargeable SCS devices, while beneficial from a cost and revision rate perspective, introduces a patient compliance requirement that is not present with primary cell generators. Rechargeable systems require patients to regularly charge their implanted device using an external charger, and failure to maintain this charging routine results in a reduction in therapy efficacy as battery levels decline. Patients who are non-compliant with charging schedules may experience symptom recurrence and reduced satisfaction with the therapy, which can result in discontinuation. This compliance burden may make rechargeable devices less suitable for certain patient populations, including elderly patients or those with limited manual dexterity, and represents a structural limitation on the ability of rechargeable systems to fully replace non-rechargeable alternatives across all patient profiles.

Patent Infringement Constraints

Nevro has implemented its patented HF10 high-frequency therapy in its SCS systems since 2010, a technology that has received FDA labeling indicating superiority compared to traditional SCS therapy. In early 2019, Nevro initiated a patent infringement lawsuit against Stimwave, a company developing minimally invasive SCS devices that had enabled its systems to operate at 10 kHz. The lawsuit resulted in a partial injunction against Stimwave that limits Stimwave and other SCS competitors to stimulation frequencies below 3 kHz. This effectively leaves Nevro as the sole provider of paresthesia-free high-frequency SCS therapy at 10 kHz, creating a meaningful competitive moat in this clinically differentiated therapy segment and constraining the ability of other manufacturers to compete directly in the high-frequency stimulation space.

Market Coverage and Data Scope

• Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
• Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and technology trends shaping demand.
• Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
• Data sources: Primary interviews with neuromodulation device industry leaders and implanting physicians, regulatory data, hospital procurement data, import and export data, and the iData Research internal database.
• Care settings: Hospitals, ambulatory surgery centers, and pain management and neurology specialty clinics.

Markets Covered and Segmentation

• The neuromodulation device market is analyzed across five therapy categories. Each is assessed by procedure volume, unit volume, ASP, and market value with historical and forecast data:
• Spinal Cord Stimulation (SCS) Market
• ◦ Device Type: Generators and Leads
• Deep Brain Stimulation (DBS) Market
• Sacral Nerve Stimulation Market
• Vagus Nerve Stimulation Market
• Gastric Electric Stimulation Market

Competitive Analysis

Medtronic was the leader in the global neuromodulation device market in 2025. The company competes through its InterStim therapy system product line, a sacral nerve stimulation platform used to treat overactive bladder, non-obstructive urinary retention, and bowel dysfunction. Medtronic's broad neuromodulation portfolio, established clinical training programs, and extensive commercial infrastructure across major global markets underpin its leading market position. The company's scale across multiple neuromodulation modalities provides diversified revenue and a comprehensive presence across the five therapy areas covered in this report.

Abbott held the second-leading position in the neuromodulation device market in 2025. The company offers the Proclaim Elite recharge-free SCS system in two sizes, providing a primary cell option for patients who prefer a non-rechargeable alternative. Abbott also offers the Prodigy MRI SCS system, which is the company's smallest implantable pulse generator and incorporates BurstDR stimulation technology. Abbott remains the only competitor currently offering this specific type of burst stimulation device, providing a differentiated clinical position in the SCS market and supporting its competitive standing against larger market participants.

• Boston Scientific was the third-leading competitor in the neuromodulation device market in 2025. The company offers four distinct products within the Precision line of spinal cord stimulation systems: the Montage, Spectra, Plus, and Novi. This range of SCS platform options allows Boston Scientific to address different patient needs and physician preferences across rechargeable and non-rechargeable configurations and across varying levels of programming sophistication. The breadth of the Precision portfolio supports coverage across multiple segments of the SCS market and reinforces Boston Scientific's competitive position alongside Medtronic and Abbott.

Technology and Practice Trends

• Extended battery life: Approvals for implantable SCS battery life of up to 11 years reduce replacement procedure frequency and expand the long-term value proposition of SCS therapy for patients and payers.
• Rechargeable generator adoption: Rechargeable SCS generators are displacing primary cell alternatives due to lower revision rates, reduced long-term cost, and lower upfront device price, and are now offered by all major manufacturers.
• Device miniaturization: Reductions in generator size and weight are improving patient comfort and expanding the eligible implant population to include patients for whom earlier generation device profiles presented fit or implant site challenges.
• High-frequency stimulation: Nevro's patented HF10 therapy at 10 kHz delivers paresthesia-free stimulation and holds FDA superiority labeling over traditional SCS, maintaining Nevro's unique position in the high-frequency segment.
• Burst stimulation: BurstDR technology, currently exclusive to Abbott's SCS platform, mimics natural neural firing patterns and provides an additional stimulation mode differentiation in the SCS competitive landscape.
• Wireless and injectable devices: Minimally invasive wireless injectable SCS devices represent an emerging delivery format that may expand the candidate pool to patients or settings where conventional implant procedures present a higher clinical or logistical barrier.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• Where are the largest and fastest-growing opportunities across SCS, DBS, sacral nerve stimulation, vagus nerve stimulation, and gastric electric stimulation through 2032?
• How are rechargeable SCS generators, extended battery life, and device miniaturization reshaping product mix, revision cycles, and the long-term economics of SCS therapy?
• What is the commercial and clinical impact of Nevro's patented HF10 high-frequency stimulation technology, and how does the 3 kHz frequency constraint affect competitor product development strategies?
• How is burst stimulation technology differentiating the SCS competitive landscape, and what are the implications for physician preference and market share?
• Which device categories are gaining share across the five neuromodulation therapy areas, and how are clinical indication expansions driving incremental procedure volume?
• Which companies lead each segment and how are their product portfolios differentiated across stimulation modality, rechargeability, and device form factor?
• What is the outlook for ASP trends across generator and leads segments as rechargeable adoption grows and pricing competition intensifies?
• What are the key risks to market growth, including patient compliance challenges with rechargeable systems, patent constraints, and the pace of adoption in emerging markets?

The Global Neuromodulation Device Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail across all five therapy categories. Use it to quantify demand, benchmark competitors, prioritize product development investments, and plan commercial strategy across a large and steadily expanding market.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Neuromodulation Device Market

• 13.1 Executive Summary
  • 13.1.1 Global Neuromodulation Device Market Overview
  • 13.1.2 Competitive Analysis
  • 13.1.3 Procedures Included
  • 13.1.4 Markets Included
  • 13.1.5 Regions Included
• 13.2 Introduction
  • 13.2.1 Spinal Cord Stimulation
  • 13.2.2 Deep Brain Stimulation
  • 13.2.3 Sacral Nerve Stimulation
  • 13.2.4 Vagus Nerve Stimulation
  • 13.2.5 Gastric Electric Stimulation
• 13.3 Procedure Numbers
  • 13.3.1 Total Neuromodulation Procedures
  • 13.3.2 Spinal Cord Stimulation Procedures
  • 13.3.3 Deep Brain Stimulation Procedures
  • 13.3.4 Sacral Nerve Stimulation Procedures
  • 13.3.5 Vagus Nerve Stimulation Procedures
  • 13.3.6 Gastric Electric Stimulation Procedures
• 13.4 Market Overview
  • 13.4.1 By Segment
  • 13.4.2 By Region
• 13.5 Market Analysis And Forecast
  • 13.5.1 Total Neuromodulation Device Market
  • 13.5.2 Spinal Cord Stimulation Market
    • 13.5.2.1 Generator Market
    • 13.5.2.2 Lead Market
  • 13.5.3 Deep Brain Stimulation Market
  • 13.5.4 Sacral Nerve Stimulation Market
  • 13.5.5 Vagus Nerve Stimulation Market
  • 13.5.6 Gastric Electric Stimulation Market
• 13.6 Drivers And Limiters
  • 13.6.1 Market Drivers
  • 13.6.2 Market Limiters
• 13.7 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 13-1: Neuromodulation Device Market, Global, 2025 & 2032
• Chart 13-2: Neuromodulation Device Procedures, Global, 2025
• Chart 13-3: Total Neuromodulation Procedures by Region, Global, 2022 - 2032
• Chart 13-4: Neuromodulation Device Market by Segment, Global, 2022 - 2032
• Chart 13-5: Neuromodulation Device Market by Region, Global, 2022 - 2032
• Chart 13-6: Leading Competitors, Neuromodulation Device Market, Global, 2025

LIST OF FIGURES

• Figure 13-1: Neuromodulation Device Procedures Covered
• Figure 13-2: Neuromodulation Device Markets Covered
• Figure 13-3: Neuromodulation Device Regions Covered, Global (1 of 2)
• Figure 13-4: Neuromodulation Device Regions Covered, Global (2 of 2)
• Figure 13-5: Neuromodulation Procedures by Segment, Global, 2022 - 2032
• Figure 13-6: Total Neuromodulation Procedures by Region, Global, 2022 - 2032
• Figure 13-7: Total Neuromodulation Procedures by Country, North America, 2022 - 2032
• Figure 13-8: Total Neuromodulation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-9: Total Neuromodulation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-10: Total Neuromodulation Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-11: Total Neuromodulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-12: Total Neuromodulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-13: Total Neuromodulation Procedures by Country, Middle East, 2022 - 2032
• Figure 13-14: Total Neuromodulation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-15: Total Neuromodulation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-16: Total Neuromodulation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-17: Total Neuromodulation Procedures by Country, Africa, 2022 - 2032
• Figure 13-18: Spinal Cord Stimulation Procedures by Region, Global, 2022 - 2032
• Figure 13-19: Spinal Cord Stimulation Procedures by Country, North America, 2022 - 2032
• Figure 13-20: Spinal Cord Stimulation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-21: Spinal Cord Stimulation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-22: Spinal Cord Stimulation Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-23: Spinal Cord Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-24: Spinal Cord Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-25: Spinal Cord Stimulation Procedures by Country, Middle East, 2022 - 2032
• Figure 13-26: Spinal Cord Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-27: Spinal Cord Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-28: Spinal Cord Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-29: Spinal Cord Stimulation Procedures by Country, Africa, 2022 - 2032
• Figure 13-30: Deep Brain Stimulation Procedures by Region, Global, 2022 - 2032
• Figure 13-31: Deep Brain Stimulation Procedures by Country, North America, 2022 - 2032
• Figure 13-32: Deep Brain Stimulation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-33: Deep Brain Stimulation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-34: Deep Brain Stimulation Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-35: Deep Brain Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-36: Deep Brain Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-37: Deep Brain Stimulation Procedures by Country, Middle East, 2022 - 2032
• Figure 13-38: Deep Brain Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-39: Deep Brain Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-40: Deep Brain Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-41: Deep Brain Stimulation Procedures by Country, Africa, 2022 - 2032
• Figure 13-42: Sacral Nerve Stimulation Procedures by Region, Global, 2022 - 2032
• Figure 13-43: Sacral Nerve Stimulation Procedures by Country, North America, 2022 - 2032
• Figure 13-44: Sacral Nerve Stimulation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-45: Sacral Nerve Stimulation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-46: Sacral Nerve Stimulation Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-47: Sacral Nerve Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-48: Sacral Nerve Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-49: Sacral Nerve Stimulation Procedures by Country, Middle East, 2022 - 2032
• Figure 13-50: Sacral Nerve Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-51: Sacral Nerve Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-52: Sacral Nerve Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-53: Sacral Nerve Stimulation Procedures by Country, Africa, 2022 - 2032
• Figure 13-54: Vagus Nerve Stimulation Procedures by Region, Global, 2022 - 2032
• Figure 13-55: Vagus Nerve Stimulation Procedures by Country, North America, 2022 - 2032
• Figure 13-56: Vagus Nerve Stimulation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-57: Vagus Nerve Stimulation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-58: Vagus Nerve Stimulation Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-59: Vagus Nerve Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-60: Vagus Nerve Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-61: Vagus Nerve Stimulation Procedures by Country, Middle East, 2022 - 2032
• Figure 13-62: Vagus Nerve Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-63: Vagus Nerve Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-64: Vagus Nerve Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-65: Vagus Nerve Stimulation Procedures by Country, Africa, 2022 - 2032
• Figure 13-66: Gastric Electric Stimulation Procedures by Region, Global, 2022 - 2032
• Figure 13-67: Gastric Electric Stimulation Procedures by Country, North America, 2022 - 2032
• Figure 13-68: Gastric Electric Stimulation Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 13-69: Gastric Electric Stimulation Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 13-70: Gastric Electric Stimulation Procedures by Country, Western Europe, 2022 - 2032
• Figure 13-71: Gastric Electric Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 13-72: Gastric Electric Stimulation Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 13-73: Gastric Electric Stimulation Procedures by Country, Middle East, 2022 - 2032
• Figure 13-74: Gastric Electric Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 13-75: Gastric Electric Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 13-76: Gastric Electric Stimulation Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 13-77: Gastric Electric Stimulation Procedures by Country, Africa, 2022 - 2032
• Figure 13-78: Neuromodulation Device Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 13-79: Neuromodulation Device Market by Region, Global, 2022 - 2032 (US$M)
• Figure 13-80: Neuromodulation Device Market, Global, 2022 - 2032
• Figure 13-81: Units Sold by Region, Neuromodulation Device Market, Global, 2022 - 2032
• Figure 13-82: Average Selling Price by Region, Neuromodulation Device Market, Global, 2022 - 2032 (US$)
• Figure 13-83: Market Value by Region, Neuromodulation Device Market, Global, 2022 - 2032 (US$M)
• Figure 13-84: Spinal Cord Stimulation Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 13-85: Spinal Cord Stimulation Market, Global, 2022 - 2032
• Figure 13-86: Units Sold by Region, Spinal Cord Stimulation Market, Global, 2022 - 2032
• Figure 13-87: Average Selling Price by Region, Spinal Cord Stimulation Market, Global, 2022 - 2032 (US$)
• Figure 13-88: Market Value by Region, Spinal Cord Stimulation Market, Global, 2022 - 2032 (US$M)
• Figure 13-89: Generator Market, Global, 2022 - 2032
• Figure 13-90: Units Sold by Region, Generator Market, Global, 2022 - 2032
• Figure 13-91: Average Selling Price by Region, Generator Market, Global, 2022 - 2032 (US$)
• Figure 13-92: Market Value by Region, Generator Market, Global, 2022 - 2032 (US$M)
• Figure 13-93: Lead Market, Global, 2022 - 2032
• Figure 13-94: Units Sold by Region, Lead Market, Global, 2022 - 2032
• Figure 13-95: Average Selling Price by Region, Lead Market, Global, 2022 - 2032 (US$)
• Figure 13-96: Market Value by Region, Lead Market, Global, 2022 - 2032 (US$M)
• Figure 13-97: Deep Brain Stimulation Market, Global, 2022 - 2032
• Figure 13-98: Units Sold by Region, Deep Brain Stimulation Market, Global, 2022 - 2032
• Figure 13-99: Average Selling Price by Region, Deep Brain Stimulation Market, Global, 2022 - 2032 (US$)
• Figure 13-100: Market Value by Region, Deep Brain Stimulation Market, Global, 2022 - 2032 (US$M)
• Figure 13-101: Sacral Nerve Stimulation Market, Global, 2022 - 2032
• Figure 13-102: Units Sold by Region, Sacral Nerve Stimulation Market, Global, 2022 - 2032
• Figure 13-103: Average Selling Price by Region, Sacral Nerve Stimulation Market, Global, 2022 - 2032 (US$)
• Figure 13-104: Market Value by Region, Sacral Nerve Stimulation Market, Global, 2022 - 2032 (US$M)
• Figure 13-105: Vagus Nerve Stimulation Market, Global, 2022 - 2032
• Figure 13-106: Units Sold by Region, Vagus Nerve Stimulation Market, Global, 2022 - 2032
• Figure 13-107: Average Selling Price by Region, Vagus Nerve Stimulation Market, Global, 2022 - 2032 (US$)
• Figure 13-108: Market Value by Region, Vagus Nerve Stimulation Market, Global, 2022 - 2032 (US$M)
• Figure 13-109: Gastric Electric Stimulation Market, Global, 2022 - 2032
• Figure 13-110: Units Sold by Region, Gastric Electric Stimulation Market, Global, 2022 - 2032
• Figure 13-111: Average Selling Price by Region, Gastric Electric Stimulation Market, Global, 2022 - 2032 (US$)
• Figure 13-112: Market Value by Region, Gastric Electric Stimulation Market, Global, 2022 - 2032 (US$M)
• Figure 13-113: Leading Competitors, Neuromodulation Device Market, Global, 2025